Small Cell Lung Cancer Trials

Talazoparib and Thoracic RT for ES-SCLC Identifier:             NCT04170946     
This study is currently recruiting participants.
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy.
Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Princess Margaret Cancer Center, Toronto
Contact: Benjamin Lok, MD    416-946-4501 ext 5819    [email protected]  

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (SCLC) Identifier:             NCT04894591     
This study is currently recruiting participants.
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
New Brunswick
Horizon Health Network, The Moncton Hospital, Moncton
Nova Scotia
Cape Breton Cancer Centre, Sydney
Southlake Regional Health Centre, Newmarket
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Centre, Toronto
CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi
Centre integre de sante et de services sociaux de Chaudiere-Appalaches Levis, Lévis
Integrated Health and Social Services Center of the Lower St. Lawrence (CISSS BSL), Rimouski
CIUSSS de l'Estrie – CHUS, Sherbrooke
Quebec Heart and Lung Institute (IUCPQ-UL), Québec